Radiotherapy for Extracranial Oligometastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
More and more evidence suggests that local radiotherapy can improve the outcomes for patients
with oligometastatic disease. The purpose of this study is to assess the impact of
radiotherapy, compared with standard systemic therapy alone, on survival, local control and
toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are
randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT
arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three
factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. >2), hormone
receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy,
the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
China-Japan Union Hospital, Jilin University Liaoning Tumor Hospital & Institute Peking Union Medical College Hospital Shanxi Province Cancer Hospital Taizhou Hospital of Zhejiang Province West China Hospital Wuhan University